Skip Navigation LinksHome > October 2007 - Volume 26 - Issue 9 > Management of Severe Allergic Conjunctivitis With Topical Cy...
doi: 10.1097/ICO.0b013e31812dfab3
Clinical Science

Management of Severe Allergic Conjunctivitis With Topical Cyclosporin A 0.05% Eyedrops

Ozcan, Altan A MD; Ersoz, T Reha MD; Dulger, Erol MD

Collapse Box


Purpose: To evaluate the efficacy of topical cyclosporin A 0.05% in the management of severe allergic conjunctivitis.

Methods: Seven patients with severe allergic conjunctivitis who were not responding to topical steroids, antihistamines, and mast cell stabilizers were given topical cyclosporin A 0.05%. All patients had an active disease when they were included in the study. Signs and symptoms were recorded before and after treatment.

Results: Seven patients, 6 boys and 1 girl, 6-14 years old, 6 with vernal keratoconjunctivitis and 1 with atopic keratoconjunctivitis, were enrolled in the study. Treatment with topical cyclosporin A 0.05% decreased the severity of symptoms and clinical signs significantly after 6 months (P < 0.05, Wilcoxon signed rank test). In addition, the need for steroids was reduced or even stopped. The patients experienced no side effects during the follow-up periods (mean, 14.0 ± 2.1 months; range, 8-18 months).

Conclusions: Topical cyclosporin A is an effective treatment in the management of severe allergic conjunctivitis with a benefit as a steroid-sparing agent.

Copyright © 2007 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.